Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor-Reference-Cited by-同舟云学术

Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor

Published:2016-09 Issue:6 Volume:63 Page:976-989
ISSN:1097-2765
Container-title:Molecular Cell
language:en
Short-container-title:Molecular Cell

Author:

Zhang Boyu,Kwon Oh-Joon,Henry Gervaise,Malewska Alicia,Wei Xing,Zhang Li,Brinkley William,Zhang Yiqun,Castro Patricia D.,Titus Mark,Chen Rui,Sayeeduddin Mohammad,Raj Ganesh V.,Mauck Ryan,Roehrborn Claus,Creighton Chad J.,Strand Douglas W.,Ittmann Michael M.,Xin Li

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference41 articles.

1. Etiology, epidemiology, and natural history of benign prostatic hyperplasia;Bushman;Urol. Clin. North Am.,2009

2. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis;Cutolo;Ann. N Y Acad. Sci.,2002

3. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis;De Gendt;Proc. Natl. Acad. Sci. USA,2004

4. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation;Debelec-Butuner;Mol. Carcinog.,2014

5. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment;Demehri;Cancer Cell,2009

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor deficiency-induced TUG1 in suppressing ferroptosis to promote benign prostatic hyperplasia through the miR-188-3p/GPX4 signal pathway;Redox Biology;2024-09

2. Prostate cancer stem cells and their targeted therapies;Frontiers in Cell and Developmental Biology;2024-08-08

3. Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia;Biology Direct;2024-08-02

4. TIAM1 signaling drives prostatic budding and branching phenotypes and is a potential therapeutic target for BPH;2024-02-05

5. Shuangshi Tonglin Capsule treats benign prostatic hyperplasia through the ROS/NLRP3 signaling pathway;International Urology and Nephrology;2023-12-01